Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report

In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2020-05, Vol.13 (2), p.544-549
Main Authors: Megaro, Giacomina, Rossi, Luigi, Ceddia, Serena, Sinjari, Marsela, Mannino, Adele, Gozzi, Elisa, Cosimati, Antonella, Brandi, Martina, Bitca, Victoria, Toscani, Ilaria, Cimino, Giuseppe, Tomao, Silverio
Format: Article
Language:English
Subjects:
bilateral breast cancer
Biology
Biopsy
Breast cancer
Cancer therapies
Case Report
Case reports
Chemotherapy
contralateral breast
Ejection fraction
Endocrine therapy
Gene amplification
Health risk assessment
Hematology
infiltrating ductal carcinoma
infiltrating lobular carcinoma
Mammography
Medical imaging
Medical prognosis
Metabolism
metachronous cancer
Metastasis
Mutation
Oncology
Patients
Risk factors
synchronous cancer
Tomography
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered a singular disease to a multiform one, according to current research focused on biological markers such as HER2, ERs, and PRs, with important implications in clinical, prognostic, and therapeutic features.
ISSN:1662-6575
1662-6575
DOI:10.1159/000507433